Distinct Immune Subtypes in Type 1 Diabetes: Implications for Disease Progression and Personalized Immunotherapy

Highlight

This study identifies two age-independent immunological subtypes in new-onset type 1 diabetes patients, each with unique transcriptomic signatures, immune cell phenotypes, and differential responses to immunotherapies such as anti-CD20 and CTLA4-Ig. These subgroups also show significant variation in post-onset C-peptide decline rates, underscoring their relevance to disease progression and treatment efficacy.

Study Background

Type 1 diabetes (T1D) is an autoimmune disorder characterized by immune-mediated destruction of pancreatic beta cells, leading to insulin deficiency. Despite advances, heterogeneity in immune pathogenesis and clinical course complicates diagnosis, prognosis, and treatment. A deeper understanding of immunological diversity at disease onset is critical to developing precision medicine strategies that can improve patient outcomes. The present study addresses this by leveraging plasma-induced transcriptional profiling and immunophenotyping to dissect immune heterogeneity in newly diagnosed T1D individuals.

Study Design

The investigation analyzed pre-intervention plasma samples from 560 participants enrolled in six distinct immunotherapy clinical trials targeting new-onset T1D. Using a plasma-induced transcriptional bioassay combined with a standardized reporter cell population, the authors identified highly variable transcripts across trials. Unsupervised clustering approaches delineated immune subtypes. Subsequent phenotypic analyses, cytokine profiling, and independent cohort validation were performed to characterize these subtypes immunologically and clinically. The study also evaluated differential therapeutic responses to anti-CD20 and CTLA4-Ig agents in these subgroups.

Key Findings

The analysis revealed 2,854 transcripts with high variability, enabling stratification of patients into two stable immune subtypes that were independent of age (p=1.4 × 10⁻¹⁴) and stable over longitudinal follow-up, indicating they reflect intrinsic immune states rather than transient activity.

Subtype 1 Characteristics:

• Predominantly included participants with neutral or low-risk HLA haplotypes.
• Youngest individuals within this group exhibited the fastest C-peptide decline, indicative of rapid beta cell loss (p<0.05).
• Elevated plasma levels of cytokines and chemokines, supporting a proinflammatory milieu.
• Increased frequency of circulating CD4⁺CXCR3⁺CCR6^– Th1 T cells (p<0.05), reflecting a Th1-driven immune response.
• Showed better therapeutic responses to anti-CD20 treatment, which targets B cells.

Subtype 2 Characteristics:

• Enriched for individuals with elevated insulin autoantibody titres, a marker of autoimmunity.
• Higher plasma levels of microRNAs miR-155-5p and miR-409-3p (p<0.05), which have immune regulatory roles.
• Displayed a superior response to CTLA4-Ig therapy, which modulates T cell responses.
• Therapeutic benefit related to a pronounced reduction in CD4⁺CD45RO⁺CD62L⁺ central memory T cells (p=8.1 × 10⁻⁵) and preservation of regulatory T cells (Tregs) (p=0.02), suggesting immune modulation favoring tolerance.

These distinct immune profiles link to differential disease progression trajectories and treatment outcomes, supporting biologic and clinical heterogeneity in T1D.

Expert Commentary

This study represents a significant advance in the stratification of type 1 diabetes based on immunological profiling rather than clinical characteristics such as age. The use of a plasma-induced transcriptional bioassay offers a novel means to capture systemic immune states driving disease pathogenesis. The correlation of immunophenotypes with treatment responses to immunotherapies targeting B cells or T cells suggests that personalized immunointervention is feasible and may enhance therapeutic efficacy.

However, limitations include the reliance on trial participants who may not fully represent the broader T1D population and the need for further investigation into mechanistic underpinnings and long-term clinical outcomes. Future studies incorporating multi-omics, longitudinal immune monitoring, and larger diverse cohorts will be critical to validating and translating these findings into practice.

Conclusion

This comprehensive immunological subtyping of new-onset type 1 diabetes underscores the existence of distinct immune pathways influencing disease progression and therapeutic response. The identification of these age-independent immune subgroups enables a move toward precision medicine in T1D, optimizing immunotherapy choices to individual immune profiles and potentially improving preservation of beta cell function. Such insights pave the way for tailored prevention and treatment strategies addressing the unmet clinical needs in this heterogeneous autoimmune disease.

Funding and ClinicalTrials.gov

The study analyzed samples from six immunotherapy trials; details of funding sources and trial registration numbers can be accessed via the original publication. All microarray gene expression data have been deposited in the NCBI Gene Expression Omnibus (accession no. GSE302205).

References

• Bedrat A, Truchan NA, Pant T, et al. Age-independent immune subtypes in type 1 diabetes exhibit distinct post-onset progression rates and immunotherapeutic responses. Diabetologia. 2026 Jul 11. PMID: 42432282.
• Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001; 358(9277):221–229.
• Roep BO, Thomaidou S, van Tienhoven R, et al. Type 1 diabetes mellitus as a disease of the beta-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17(11):653–664.
• Krischer JP, Cuthbertson D, Schatz DA, et al. The immune profile of new-onset type 1 diabetes in youth reveals pathophysiological heterogeneity. Diabetes Care. 2020;43(6):1356–1363.